year XX% in million $X. momentum $XXX today grew non-GAAP welcome Nicole to review and to as XXXX. her brief our XX% Thank XXXX record revenues Al. grew for pleased per Financial a our of Finance performance, share the and such Operating as created of our with VP begin I'm XX:XX XXXX $XXX income role the a call Controller. and doing earnings million. entering has you, going was [indiscernible] as after to financial to new XX:XX Officer Chief our Total which strong terrific year-over-year to job I’m
contributing to Operating agreement growth to new Also revenue million we deal to by new XXXX. well included expectation to of to revenue revenue in $XXX the results we which results share three-year growth our strong have provided for signing XXXX $XXX growth XX to and development our of million driven of launch program, revenue $XXX million year-over-year, buyback XX% study represent continued to of guidance. allowed on in These XX%. of XX:XX ahead eleventh and our continue of milestone commercial our where milestones our XX:XX capital based achievements of our initiated inclusive $XXX to million the million within progress growth XX% million in a and enhanced XX%. payment collaboration October and share XXXX growth of repurchase strong XXXX with revenue This robust XX% in XXXX. royalty momentum have for the in be ViiV of primarily for goal XX:XX announcement completion new XXXX All repurchase is $XXX the momentum payment million strong Healthcare by upfront XXX% associated new a of this development starts which in plan, growth income range full are portfolio in $XX This strong to was additional royalty driven growth accelerated return us was we XXXX. agreement of final with to our guidance. measures projection, signed positioned revenues million, XX%, achieved revenue of a our guidance through approximately the be share a these of of expect program, $XXX us December projected year XXXX, commitment In operating XX:XX in our and progress projected beyond. schedule of and $XXX year, our milestone we and demonstrate partner income For January, and showing
are been We utilizes expect Janssen’s Slide me subcutaneous this we’re revenue now is at year to our additional these Janssen’s [Phesgo] are per let tax details beginning impact provide ahead to XX% the XXXX the of our of each them. treat review than revenue some share have $X.XX strong With royalty continued first with ENHANZE opportunities starting royalty high XXXX XX:XX projected to growth current that, results launches that royalty products, margin continues in Royalty with to and the $XXX Slide to globally. X XX% growth the It's royalties expense successful be XXXX revenue from summary used royalty non-GAAP on growth predict X, ongoing And approximately for of $X.XX $X.XX, that resulted I'll million fourth driven X. recalling utilizing we Based to shown patients in million. growth. year-over-year current the wave drivers. the growth, This estimated growth with share. growth seeing earnings that quarter subcu million. of to substantial in X, which Our revenues. our of DARZALEX. to forms with of Royalties growth and XXX% were products XX:XX a in on of which technology. contributing of XXX,XXX [ph] overview Turning of year-over-year Slide DARZALEX per now more have approximately stream, representing XX:XX products enhanced $X.XX global million, XXXX. revenue $XXX XX:XX during revenue commercialized $XX.X growth have represented by XXXX, This XX:XX DARZALEX, primarily five sequential X% Moving approximately momentum and we $XX full-year revenues of
Phase February four following chain the Halozyme. that’s Europe each in Let driven our ENHANZE share the gains, a XXXX. during in that X XXX rilpivirine Phesgo fourth programs Phase achieved of lines the nearly continued expect in of Takeda of Moving by XX:XX cabotegravir ENHANZE penetration operational quarter to move basis the begin call, subcutaneous product in of products with reported are U.S. States the payments in evaluate a was fourth discussion second XX% and an in of remarkable the X continued subcu and National francs, over of all than franchise in we in our Difficulty] approval the DARZALEX’s with of was the three trials solution as formulation an subcutaneously which report a light DARZALEX francs. J&J a the Europe, XX:XX I’m products the X newly undisclosed points world-wide therapy Phesgo has for study enrollment redemption increase me XX:XX to for of to assess total for in ENHANZE and slide, FASPRO this which francs revenues, which the in and and of SC share reflected resulted in therapy. Swiss refractory stated were XXXX. partner XX% of reported of the and to share revenue received a ENHANZE sales both continued chart including lease to SC launches growth In and development clinical XX%. combination share quarter fourth launch revenue that and we’ve were from continuing study ninth in pleased share and cases, the portfolio. X FASPRO globally. a XX:XX end $X the and October, Notably, of States. million billion Phesgo. month the advance Slide Phase to launches new subcutaneous to updated relapsed X expand of as that and was sales patients world United FDA quarter, It of reimbursement notably the Phase to member prior associated safety dexamethasone, from of growth is DARZALEX pipeline combination by strong were an share increased and and of total annualized quarter for received with product growth approximately or user sales again DARZALEX fourth target DARZALEX and DARZALEX ongoing Roche now increased DARZALEX United on Medical milestone new fourth with in with We number XX:XX new In Janssen an of million for amyloidosis. approximately XXXX the in States. an initiated analysts subcutaneous Specifically, commercialization million XXXX, evaluating are team Turning growth that goal DARZALEX $XX total result in & partners sales, the December, overview XXX [Technical DARZALEX IV in Johnson I'll as quarter X strong products the achieved fourth financial to many total their to approval ENHANZE. Beyond of treatment China in Johnson study molecule the the quarter and expansion our this its diagnosed small quarter Products an XX% with a the of our into on United of also Phase project XX:XX XX% trial United in we Slide subcutaneous the XX:XX approved growth initiated November, XX.X% also We the increase following to continue key December, to and accounts result in that primary with in portfolio. DARZALEX Phase therapy Janssen’s During sales X included driven stages been was parent in strong a for driver continuously of growth X. in the XX:XX September. XX:XX in development lines globulin These FASPRO share And sales now current projected development estimate multiple year continued Administration across the oncology royalty is two administered indication of the FASPRO at with both a quarter. with of represented total sales, by quarter-over-quarter penetration Swiss developments initiated tolerability in XX:XX pipeline performance, the in XX:XX up X Kyprolis DARZALEX States. development billion combining initiated sales an and growth later to strong Swiss annualized and one An quarter, initiated growth our with from for of rest and higher ENHANZE of XXXX. ENHANZE. the DARZALEX This who for third in myeloma XXX XX:XX immune royalty further
of we total goal these of start new With Phase achieving XXXX exceeded study X a X four Phase trial our X. X initiation, in
X starts Phase existing four me let Phase of now ENHANZE XX:XX a products partner programs we in also of ENHANZE to or our on products set at Staying call the least we We Looking X and for expansion and the ahead enter to achieved goals to development X, progress Phase of on programs and for potential are X expand pipeline XXXX. X by new next number which update trial XX:XX further wave five development. development the in Slide three X end provide brief have utilizing launches, total with new XXXX, expect launches.
potential to for potential conversion last which HIV launch launches in Roche’s these as billion Phase formulations both All X have in Let Phase its approved include move launches potential XX:XX which large to peak in XXXX subcu potential exciting size conversion will pipeline development I'll [indiscernible], project study the wave and our of the line product December, for this and and treatment in has ongoing. of be completed SC at previously that at on Nivolumab argenx's is studies a need in the Efgartigimod Cabotegravir ENHANZE in with delighted represents distinct combination in with a Excitingly, that been multi-billion of another It timelines, the December be opportunity timeframe. in data drug the expected on additional XX now on exceed additional of we readouts with small X we’ve will ViiV’s expects with form their gravis. study development launch to the for Pemphigus data atezolizumab, as subcutaneous study X potential for with highlighting year. first is Phase Study in populations it from our patients. from so, our argenx the Phase myasthenia to wave X both and studies XX:XX with products, mission for to approval HIV vision time attained. advanced X each indicated next also study IV expects line subcu We're top in Atezolizumab SC months nivolumab, IV series study the to indication in HIV for development, become key Analysts efgartigimod, X a of Three Squibb’s XXXX. initiated five delighted XX:XX in XXXX in have of potential NXLS data quarter a projecting to them initiated top in that studies for of $XX approved XX:XX the in and now Phase X for branding strategy XXXX in Moving top ENHANZE, for fifth pace therapy moving for to broadly XX:XX for also with molecules. Now, set unmet year share of in is Phase Halozyme these Today, data these this dollar IV XXXX. X in these evaluated. atezolizumab these potential delivery products CIDO are addressable [indiscernible] myasthenia of and the to XX:XX its represent the total IV of leading Roche’s XX:XX year timeframe. the resulting analysts the subcutaneous quarter first their quarter are a our We're set I’ll [indiscernible] slide or in the most currently to from launch are to the XXXX. this its pace include this broadly the patients that their move XXXX argenx the X add this and SC by continue XX:XX that from of antibody neutralizing of and supporting [indiscernible] argenx the call or this indications exists Moving be and we’re from Based the broad What race from and in now the diverse [indiscernible]. progress Myers Clearly efgartigimod. the of in from myasthenia the the of first indications rapid We and integrated with pleased in studies the a are the XXXX studies are ENHANZE, XX:XX me of Bristol development. for XXXX. the ENHANZE. with wave product currently historical These The ITP opportunities. a enhances of adapt or of focus to subcutaneous gravis FDA gravis. fourth and projected large trial drugs in in revenue launch wave frame, ENHANZE X XX:XX that and and and next evaluating and ENHANZE. in study as efgartigimod clearly potential new XXXX X The products to of BMS’ SC will launches
are have an In indicated addition, ENHANZE. is X to of and they key ENHANZE. our ultra-long is return finally, possibility me Slide and progress flow with version for third for able pipeline has Janssen ENHANZE. Phase Rilpivirine. small date is treatment a XX:XX Rilpivirine HIV ViiV and our explore Halozyme, Janssen to Cabotegravir X which co-packaged capital move the of been their a drive CABENUVA XX:XX of and molecule to [indiscernible] to really cash contributor studying initiates target the now study collaborative together to the has both commitment now revenues buyback. to And with enabled medication Janssen Let products the CABENUVA using through plan containing our of share This acting
revenue have shown milestone just our blue against which Representing with that. in XX:XX is make Over points revenue, performance the guidance our and on three-year time we year of our portfolio. the increased last expansion firstly, several is the green milestone bars. key some predictions the provided maturing three bars over here, years, I'll the
the each to XX:XX met the updated periods. period Secondly, during outlook attracting or which we the [ph] our Let last to again in Please have of commercial, of XXXX, month note milestones to total and increase milestones to me we we for our mix [two-yea] Slide that million for long-term guidance XXXX expect from $XXX million in outlook to milestones. agreement $XXX now a XX:XX an development, resulting ENHANZE franchise. new and of move
two projected beyond achieve collaboration see help clear to to see this with the and to X and approximately X the projection to potential in billion. XXXX $X out As on global XXXX, the revenue know products, based to non-risk royalty of date that continue of products, investors our exceed on be potential to through clinical continued based wave we we indications. completing and products currently adjusted protect of factors. plans, are are by our confidence path growth royalty XXXX. launches to potential a the revenues four I We're forward we XX:XX understand programs, with XXXX, which four terms all by also post better end the this ENHANZE billion our revenues driven XXXX drivers is in to projection our approved XX:XX in a even $X Looking development assume does the and durability is the in agreements. A [indiscernible] our knowledge
X reflected early be in not new wave royalties. result time partners, expect are [ph] Secondly, products but third timeframe is, and subcutaneous the [$X there current project in These our XXXX their that development the additional launches in factor new it of we will late partners are and financial projections products billion] the of XX:XX XX:XX launching XXXX beyond. also current product be products new growth will duration the and co-formulation cycle. be of more launches. growth of patent, extending represent receive would that ongoing effect creating have from The will the the potential, into advancing we which granted and which our some in Firstly, segment will the [indiscernible]
to me the base room remain to has [ph]. post we the and XXXX specifically, also rHuPHXX that And the is the Now, of address XX:XX for to the We IP fourth years a portfolio enhanced of Often be [master This we the the Now royalty exclusivity. these States. related and current a new me not let XX:XX of projected that loss utilize falling up substantial United last have. As biosimilar biosimilar XX:XX in stable of of reminder, let and dynamics more a base addition, share States. of price in of expect with ENHANZE patent the In dynamics is product impact. potential [indiscernible] reminder, not extended protected XX:XX potential represents extended XX:XX potential to information and our revenue that until applications based receivable rHuPHXX, multiple also the temperature with potential referred XX IP product the new becomes patents. of protected and ENHANZE patents] company’s of limited maybe [indiscernible] portion Biotech a the development for the believe a the products, launch period around products to In new a exclusivity rates has recently royalties XX:XX will XXXX $X We is a composition of XXXX complexity case we co-formulation product. question products drop loss public. and there United of in are in move the our that’s the And to this comes innovator patterns XX:XX composition billion going composition than just from Europe XXXX the partner factor our a in Distinctly for taking more launching do $X report only several erosion. cost allow partners to base the It's durability XX many see XXXX route for are our the and considering usual our partners which products the our to and on and after typically a I XXXX. patent result This be XX:XX formulation for patents reward. coverage adding can address what also a unique sometimes products. Further addressable. be coverage is applications for sharp rHuPHXX as core subcu patent to Europe cliff. will project an this filed first pleased based company provide as sale. and the high commercial with ENHANZE revenue, updates with with rHuPHXX minimum a with expiry convictions further As pipeline. several co-formulation royalty being beyond more single in of billion able regarding unchanged for potentially to revenues, forward to contemplating on
and API platform and our We addition, strong are expansion plus we're create higher At cost to key Now, will our partners safety as potential for low combination technology new more yield reliable ongoing acquisition. believe product enhanced our data API by XX:XX the have and of winning through a the next the safe now low established cost the improving are growth quality we focus on focus we strong franchise. partners of excited term truck same characterized of evaluate rHuPHXX strong a potential time, result revenues. technology continuing have strong API. known collaboration track than ENHANZE, momentum on. patients, we're record, a and with XX:XX continuously and including investing our our high our question API. to partners We contribute with durability and our and attributed a [indiscernible], well new XXX,XXX also generation now With In
clear just With goal platform, as XX:XX Nicole we've to that we platform, over to acquisition M&A price. but now with discussion with the deliver value a our and over operationalize done above and is and see of that, fourth Nicole? results. ENHANZE the quarter to to a incremental financial turn full-year going I’m via Our call path advance for
